Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses

School of Public Health

1-1-2020

Cost Effectiveness Of A Produce Prescription Intervention
Danielle Raso
danielle.raso@yale.edu

Follow this and additional works at: https://elischolar.library.yale.edu/ysphtdl
Part of the Public Health Commons

Recommended Citation
Raso, Danielle, "Cost Effectiveness Of A Produce Prescription Intervention" (2020). Public Health Theses.
1985.
https://elischolar.library.yale.edu/ysphtdl/1985

This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar –
A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an
authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information,
please contact elischolar@yale.edu.

Cost Effectiveness of a Produce Prescription Intervention

Danielle Raso, Masters of Public Health, 2020.

Danielle Raso, Masters of Public Health, 2020
Department of Health Policy and Management, Yale School of Public Health

Primary Advisor: David Paltiel, MBA, PhD
Secondary Advisor: Mona Sharifi, MD, MPH

ABSTRACT
In this study, we examined the effectiveness, cost, and cost-effectiveness of a produce
prescription program. The program analyzed in this study is run by Community Health and
Social Services (CHASS) Center, a Federally Qualified Health Center (FQHC) in Detroit,
Michigan. The prescription produce intervention begins with eligibility screening and referral by
patients’ physicians at clinical visits for eligibility. Eligible patients are then given
“prescriptions” for free fruits and vegetables that they can exchange at participating farmers
markets or farm stands. Farmers markets also host cooking demonstrations and distribute healthy
recipes. Finally, coordinators and volunteers follow up with patients and provide nutrition
education with a standardized nutrition curriculum. We observed an average effect size of .532
unit reduction in hemoglobin A1c and a cost effectiveness ratio is $1,901 per one unit change in
HbA1c, with 95% confidence intervals of 1208.72; 3016.96.
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INTRODUCTION
Over the course of the last few decades, there have been a number of shifts in the average
American diet that have fueled the obesity crisis, including increased sugar intake, decreased
fruit, vegetable, and fiber intake, and an overall increase in calories consumed each day.1 Studies
have shown that even without reducing calories consumed, increasing fruit and vegetable
consumption has independent benefits to patients’ diets by increasing their fiber intake, reducing
sodium and fat intake, and increasing the micronutrient content.2 Increasing the consumption of
fruits and vegetables can improve health by promoting healthy weight and reducing the risk of
heart disease, stroke, some types of cancer, digestive problems, and spikes in blood sugar3.

There are grave disparities in access to healthy foods based on income, race, geographic location,
and immigration status, which in turn drive disparities in overall health and quality of life.4
Prescription produce programs are a relatively new type of intervention which have the potential
to reduce health disparities resulting from differential access to healthy food. They allow
healthcare providers to act when they encounter patients with food insecurity or whose health is
suffering because they find fruits and vegetables to be prohibitively expensive. In addition to
providing free or discounted access to produce, many prescription produce programs also
attempt to address other cultural and socio-contextual barriers to accessing healthy food by
providing educational and skill-building programming such as cooking demonstrations,
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suggestions of meal plans for the whole family, and nutritional information at the point of
purchase.

There have been few studies published that examine the effectiveness of produce prescription
programs, but the existing literature points to significant dietary improvements and reductions in
food insecurity from similar programs.56789 One study showed a clinically-significant decrease in
BMI among participants in produce prescription program retrospectively compared to a
nonintervention group.10 Another observational pre-post study showed clinically-significant
improvement in hemoglobin A1C (HbA1c) , which is associated decreased risk for type II
diabetes.11 Most studies have shown an increase in participant-reported consumption of fruits
and vegetables.
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In this study, we examined the effectiveness, cost, and cost-effectiveness of a produce
prescription program. We hypothesized that the produce prescription program will result in
statistically significant improvement in HbA1c among participants with diabetes and describe the
cost and cost-effectiveness of the intervention. Our aim was to inform policy-makers and clinical
decision makers interested in implementing programs to address food insecurity and to promote
good nutrition and health.

METHODS
Intervention Details:
The programs analyzed in this study are sample programs that originated from a grant
scheme that funded the administration and evaluation of several prescription produce programs
in the Detroit metropolitan area, organized through the nonprofit Eastern Market. Our primary
analysis focuses on the program by the Community Health and Social Services (CHASS) Center,
a Federally Qualified Health Center (FQHC) in Detroit, Michigan. The prescription produce
intervention begins with eligibility screening and referral by patients’ physicians at clinical visits
for eligibility. Eligible patients are then given “prescriptions” for free fruits and vegetables that
they can exchange at participating farmers markets or farm stands. Farmers markets also host
cooking demonstrations and distribute healthy recipes. Finally, coordinators and volunteers
follow up with patients and provide nutrition education with a standardized nutrition curriculum.

Estimation of Effect:
To estimate the effect of the program, we looked at its effect on reduction in HbA1c,
because it is a reliable and clear indicator of effects of increased vegetable consumption. In

previous research on this set of programs, there has been more sufficient evidence showing a
reduction of HbA1c than there has been for any effects on weight or blood pressure, likely
because HbA1c is more reliably dependent on change in diet. CHASS and HFHS are vastly
different care settings, and while their efforts for the prescription produce programs were
coordinated and similar, the implementing environment was too different to equate their
programs. As the costs of the two interventions as implemented in CHASS and HFHS are not
equivalent, we considered the effects of their interventions separately.

Population
Participants from CHASS are low-income patients seen for primary care visits, and have
been diagnosed with diabetes. As reported in prior studies, most participants were female, with
an average age of 49, and have a household income of less than $24,999. In 2015-2016, 44% of
patients were African American, 37% were Hispanic/Latino, and 19% were either Caucasian,
Native American, or selected “other”.12 The data analyzed for this study did not include
demographic level data about participants.

Data
Yale’s Institutional Review Broad (IRB) approved this study as nonhuman research. For
the pre intervention HbA1c, post intervention HbA1c, year of participation, and number of visits
was shared with the evaluator, along with costing data. No identifying information was shared
with the research team.
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Statistical Analysis
We first checked the normality of the data using a Shapiro test on the variance. We
performed a series of paired t-test on the pre and post intervention HbA1c. We looked at the
effect estimates of the data in its entirety and for CHASS, examined potential data limited to
participants who completed more than 1 visit, more than 2 visits, more than 3 visits, and more
than 4 visits. There were 171 total participants analyzed from CHASS, though only 96 completed
4 or more visits, which is the number of visits the organization would consider the program
completed at. Participants were offered between 6 and 8 total visits, depending on year. CHASS
data comes from three different implementation years- 2015, 2017, and 2018. HFHS provided
only one year of data, from 2019, and only provided data from participants who completed all 6
offered visits. We separately tested HFHS’s effect size, also using a paired t-test.

Cost Modeling Methodology:
In conjunction with partners at HFHS, CHASS, and Eastern Market, we measured the costs of
the program using a micro-costing approach, including costs from a health systems perspective
and limited societal perspective. Due to the relative strength of CHASS’s effect data, their
program was primarily analyzed. Micro-costing involves detailed measurement and analysis of
each unit of input to the program, which is the most specific approach outlined by the 2nd edition
of Cost-Effectiveness in Health and Medicine 13. The costs were grouped into the following
categories: Screening and Connection to Treatment, Transportation Costs for Events, Capital
and Material Costs of the Events, Nutrition and Cooking Education, and General Program Costs.
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Nyman J. A. (2018). Cost Recommendations in the Second Edition of Cost-Effectiveness in Health and
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We did not include related to research and evaluation because evaluation is not a part of the
intervention and does not contribute to the effect estimates observed. Program implementers
gave a range for each unit for each time and cost wherever possible. While the time ranges
contributed represented the time spent by those working on this program, the salaries used were
not the employee’s real salaries, but Bureau of Labor Statistics (BLS) quintiles given for the
general category of their job title. To ensure that the correct BLS category was used, several
levels of similar positions were presented to the implementing team, and the team confirmed the
level most similar to the actual employees.
After compiling estimates of costs and effectiveness, we conducted probabilistic
sensitivity analyses using 1000 Monte Carlo simulations for each unit cost to examine the
uncertainty around our estimates cost and cost-effectiveness. We then conducted a one-way
sensitivity analysis around the estimate of the program director’s time costs given high levels of
uncertainty in this estimate.

RESULTS
Estimation of Effect:
Among 171 participants in the CHASS produce prescription program, mean HbA1c at
baseline was 9.556. A majority (56%) attended 4 or more of the total of XX program visits. In
paired t-tests, we observed a mean reduction in HbA1c of 0.532 (95% CI: .313%, .751%;). The
results of the t-tests stratified by levels of participation are displayed in table 1. Effect sizes range
between .532 and .927 unit reduction in HbA1c points, and are statistically significant in all cases
with the greatest mean reduction among participants who attended ≥5 visits. The mean HbA1c

level for all participants at baseline was 9.55614, representing a clinically significant 5.6
percentage point reduction in HbA1c levels14.

Table 1. Effect Estimates by Level of Participation
N
(%)

Mean change in HbA1c unit P-value
change,
95% confidence interval

All Participants

171
(100%)

.532 (.313, .751)

<.001

≥2 visits

140

.576 (.342. .811)

<.001

.635 (. 372, .898)

<.001

.768 (.481, 1.054)

<.001

.927 (.614, 1.240)

<.001

(82%)
≥3 visits

122
(71%)

≥4 visits

96
(56%)

≥5 visits

37
(22%)

For Henry Ford Health System (HFHS), we have data from the per protocol group only, with pre
and post interventions 30 participants who completed all visits to the farmers markets. Though the
sample size and for HFHS is lower, limiting our power to detect a significant difference, we
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observed an effect estimate that is nearly identical results of CHASS’s intervention, with a mean
reduction in HbA1c of 0.52% (95% CI: -.01%, 1.05%;).

Costing:
After completing 1000 Monte Carlo Simulations, we estimate an average total cost of the
CHASS produce prescription program of $59,152.66 per year, with 95% Confidence Intervals
37,413.01; 88,451.38.

Program Component
Total Costs Screening And Connection to
Treatment
Total Transportation Cost of Events
Capital and Material Costs of Farmers Markets
Total Nutrition and Cooking Education
General Program Costs
Total Average

Average Cost
$3,645.56
$555.74
$2,073.76
$9,255.85
$43,621.75
$59,152.66

95% CI (Upper)
$4,322.29
$1,081.74
$2,425.37
$15,539.69
$72,582.62
$88,451.38

95% CI
(Lower)
$3,030.80
$222.42
$1,749.80
$4,012.02
$22,467.27
$37,413.02

Putting together the cost and effect portions of this study, the cost effectiveness ratio is $1,901
per one unit change in HbA1c, with 95% confidence intervals of 1208.72; 3016.96.
The greatest amount of variation comes from the “General Program Costs” category
because the estimation of director’s time given by the organization was a wide estimation of 1220 hours a week, and the quintiles for the salary of a medical and health services director is a
highly variable category, according to the Bureau of Labor Statistics data. We performed a
sensitivity analysis on the director time unit cost because it is not only the most variable cost, but
it is also the largest cost of the categories, and the largest single unit cost in our analysis. The
sensitivity analysis shows that varying the director’s time and salary alone could change the cost
effectiveness ratio from $1019.04 to $3295.11 per unit reduction in Hemoglobin A1C. The

results of the sensitivity analysis shown in Figure 1 show the CE variation along 5 different
curves which represent the BLS salary quintiles.

Sensitivity Analysis of Director Time Cost (Hours
Spent and BLS Salary Quintile) on Cost
Effectiveness Ratio
CE Ratio (Cost: Effect)
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DISCUSSION
We examined the effectiveness and costs associated with a produce prescription program
based in a primary care setting and observed an average effect size of .532 unit change in
hemoglobin A1c and a cost effectiveness ratio is $1,901 per one unit change in HbA1c, with 95%
confidence intervals of 1208.72; 3016.96. In our base case scenario, the time of the program’s
director comprised 74% of the total costs of the intervention with a high level of variability in our
time and salary estimates. We found that varying the program director’s time in sensitivity could
vary the CE ratio between $1019.04 to $3295.11 per unit reduction in Hemoglobin A1C.
The results from our effect estimate stratified by number of visits to the farmers market
indicate a greater effect size upon each incremental increase in visits, however this does not
necessarily imply that offering a higher number of “doses” causes a greater effect size, as we do

not have the ability to control for confounding factors that may cause participants to drop out of
the program early.
Our results suggest that produce prescription programs may difficult to compare to other
interventions aimed at reduction in HbA1c, but may have similar cost effectiveness as compared
to other short term interventions to reduce HbA1c. This intervention’s cost effectiveness ratio
cannot fairly be compared to the standard of care, which is a lifestyle intervention combined with
metformin because the incremental cost effectiveness ratio produced from this research reflects
longitudinal observations15. However, a similarly short-term study of a common pharmacological
interventions, liraglutide and exenatide, showed a similar effect size (between .5-1 (Hemoglobin
A1C change) with a similar cost per unit change in HbA1c 16. The cost-effectiveness ratio is higher
than for one program that includes only nutrition and diabetes education and resulted in similar
levels of HbA1c reduction17.
The results of the micro-costing analysis and sensitivity analysis show general program
costs should be the main focus of an organization trying to replicate this program at a low cost.
Due to the low number of variables, having an employee with a lower salary coordinate the
program could affect the cost of the program dramatically, as this one unit represents nearly ¾ of
the total program costs. Having coordination represent such a large percentage of the total cost of
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the program may mean that having funding for more participants should result in economies of
scale, meaning lower cost per participant and a lower cost-effectiveness ratio.

Limitations
The primarily limitation of the data used in this analysis is that while diabetes and other
metabolic diseases this intervention addresses are chronic diseases, this intervention is very
short, consisting of just 16-18 consecutive weeks. It is obviously challenging to institute lasting
lifestyle change in this period of time, but it is also difficult to measure the results of an
intervention’s impact on chronic disease in such a short period of time. The most sophisticated
cost-effectiveness research would calculate an incremental cost effectiveness ration (ICER) and
would therefore depend on calculating a quality adjusted life year (QALY), which typically
requires an understanding of effects on lifetime mortality and quality of life18. Being able to
collect more longitudinal data from a prescription produce program would also give researchers
the ability to calculate reductions in spending on metabolic disease related care that might result
from improved glycemic control.
Another limitation is that we do not have RCT data, which is forthcoming from the
intervention at CHASS, and this data could make evidence of a consistent effect stronger. RCT
data would make us more able to detect the effect of this intervention as compared to standard
care. With the current data because, we also did not have any demographic information on that
participants so could not control for variables that may have confounding effects on why
participants were or were not able to complete the intervention.

18

Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010). Cost-Effectiveness of
Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review. Diabetes Care, 33(8), 1872.
https://doi.org/10.2337/dc10-0843

Finally, our costing data was limited by being reported retrospectively, well after the
implementation of the intervention as measured. This is inherently less reliable than directly
observed costs or time costs more minutely measured during the intervention, such as if we had
records of staff daily time logs, because retrospectively reported data may be subject to recall
bias. In particular, participant transportation data and participant time cost was difficult for staff
to estimate and while these represent a very small portion of the total cost, it would have been
better to have data from the participants themselves.
In summary, the intervention is both effective at improving glycemic control and, with a
cost effectiveness ratio of $1,000.62 to achieve an average .532 unit change in HbA1c, is more
cost effective than the “standard care” lifestyle intervention. Longer term interventions should be
tested and more research should be done about both the long term effectiveness and costeffectiveness of prescription produce interventions.

